Category Archives: Eczema

Hey Ms. Green,

What is the most eco-friendly paint for inside my home and work space, including the walls and furniture? Also, what's the greenest way to recycle paint?

Marivic in Madison, New Jersey

Here's a primer: That new-paint smell comes from ingredients that can be toxic to your health. A 2010 study found that exposure to elevated levels of volatile organic compounds (VOCs) in paintincluding propylene glycol, glycol ethers, formaldehyde, and benzeneincreases the likelihood of developing asthma and eczema.

Look for safer options with these third-party certifications, which indicate paints with less VOC content: Green Wise Gold, Master Painters Institute X-Green, and Cradle to Cradle. You can also use Green Sealcertified paints, though Green Seal doesn't factor in VOC emissions like the other eco-labels do.

I used BioShield Solvent-Free Wall Paint along with the BioShield trim enamel and wall glaze. It's been a few years, but my walls still look fresh. The paint is made with water, chalk, asbestos-free talc, and other less-toxic ingredients. It arrives looking like chalk; all you have to do is add water. BioShield sells other home-improvement products: clay paint, interior and exterior wood stains and finishes, and even beehive paint.

Paint can be flammable. Don't leave it lying around. And don't put it in the trash; that's illegal in many states. The greenest way to recycle your paint is through an extended producer responsibility programin which companies pay for the recycling of their products. You can drop off paint at one of the sites listed on paintcare.org.

View original post here:
What's the Greenest Paint for My Home? - Sierra Magazine

An experimental treatment helped asthmatics with cat allergies to spend several hours exposed to cat allergens without wheezing or coughing, a proof-of-concept study finds.

Scientists with Regeneron Pharmaceuticals, the makers of the asthma and eczema biologic drug Dupixent (dupilumab), have been exploring the use of monoclonal antibodies to reduce asthma and allergy symptoms in people with cat allergies.

The treatment uses two lab-created antibodies to Fel d1, the protein found in a cats skin and saliva thats to blame for wheezing, coughing or shortness of breath in those with asthma. The antibodies, which are given as two injections just under the skin, bind to Fel d1. The concept is that this blocks IgE antibodies circulating in the blood from binding to the cat allergy protein, preventing the allergic reaction.

In the Phase 2 trial, 56 people with cat allergy and mild asthma were given the monoclonal antibodies or a placebo. After eight days, they were exposed to cat allergens in an environmental exposure unit, a room used for controlled experiments.

Lung function tests showed the placebo group had asthma symptoms after an average of 51 minutes of exposure to cat allergen. Those in the treatment group lasted an average of more than four hours in the chamber without wheezing or shortness of breath. Four hours was the maximum time they were allowed to stay in the chamber.

Although some people in the treatment arm experienced asthma symptoms during the four-hour timeframe, over 50 percent of the active therapy arm had no reaction detected in the chamber, says Dr. Jennifer Maloney, an allergist and Regeneron executive director. Many were able to sit in there and tolerate the allergen being pumped in.

The research was presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) virtual annual meeting in late February.

Participants went back into the environmental exposure chamber again at one, two and three months after the injections. At three months, participants went longer still before having asthma symptoms when exposed to cat allergens. At four months, those who received the therapy had on average, smaller reactions on skin testing than the placebo group.

Regeneron is planning a large Phase 3 clinical trial to test the therapy in a real-world setting, Maloney says. No date has been set yet.

Fel d1 is a difficult allergen to avoid, as it clings to surfaces like bedding, carpets and clothes. Studies have shown the allergen is found in classrooms, movie theaters and other public places where there are no cats.

We know cat allergies are so pervasive. Its challenging if the cat is in the home or the home of a significant other, Maloney says. The cat is part of the family. Its easy enough for the allergist to tell patients to remove the cat from the home. As an allergist, Ive given that advice, but its not always taken kindly by families.

Maloney knows this well. As a child, she had both a cat allergy, and cats. We never even considered getting rid of the cat.

Related Reading:Nothing to Sneeze At: New Strategies to Control Cat AllergyAsk the Expert: Can Cat Allergy Develop Later in Life?Life-Changing Biologic Now Approved for Teens with Severe Eczema

See the original post here:
Cat Therapy Aims to Block Wheezing and Asthma Misery - Allergic Living

Diagnosis

No lab test is needed to identify atopic dermatitis (eczema). Your doctor will likely make a diagnosis by examining your skin and reviewing your medical history. He or she may also use patch testing or other tests to rule out other skin diseases or identify conditions that accompany your eczema.

If you suspect a certain food caused your child's rash, tell the doctor and ask about identifying potential food allergies.

Atopic dermatitis can be persistent. You may need to try various treatments over months or years to control it. And even if treatment is successful, signs and symptoms may return (flare).

It's important to recognize the condition early so that you can start treatment. If regular moisturizing and other self-care steps don't help, your doctor may suggest one or more of the following treatments:

Creams that control itching and help repair the skin. Your doctor may prescribe a corticosteroid cream or ointment. Apply it as directed, after you moisturize. Overuse of this drug may cause side effects, including thinning skin.

Other creams containing drugs called calcineurin inhibitors such as tacrolimus (Protopic) and pimecrolimus (Elidel) affect your immune system. They are used by people older than age 2 to help control the skin reaction. Apply it as directed, after you moisturize. Avoid strong sunlight when using these products.

These drugs have a black box warning about a potential risk of cancer. But the American Academy of Allergy, Asthma & Immunology has concluded that the risk-to-benefit ratios of topical pimecrolimus and tacrolimus are similar to those of most other conventional treatments of persistent eczema and that the data don't support the use of the black box warning.

Light therapy. This treatment is used for people who either don't get better with topical treatments or who rapidly flare again after treatment. The simplest form of light therapy (phototherapy) involves exposing the skin to controlled amounts of natural sunlight. Other forms use artificial ultraviolet A (UVA) and narrow band ultraviolet B (UVB) either alone or with medications.

Though effective, long-term light therapy has harmful effects, including premature skin aging and an increased risk of skin cancer. For these reasons, phototherapy is less commonly used in young children and not given to infants. Talk with your doctor about the pros and cons of light therapy.

Treatment for eczema in babies (infantile eczema) includes:

See your baby's doctor if these measures don't improve the rash or if the rash looks infected. Your baby may need a prescription medication to control the rash or to treat an infection. Your doctor may also recommend an oral antihistamine to help lessen the itch and to cause drowsiness, which may be helpful for nighttime itching and discomfort.

Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this condition.

To help reduce itching and soothe inflamed skin, try these self-care measures:

Atopic dermatitis can be especially stressful, frustrating or embarrassing for adolescents and young adults. It can disrupt their sleep and even lead to depression. And close family members of people with this condition may face financial, social and emotional problems.

Seek psychological support from counselors, support groups, friends or family.

You're likely to start by seeing your family or primary care doctor. But in some cases when you call to set up an appointment, you may be referred to a specialist in skin diseases (dermatologist).

Here's some information to help you prepare for your appointment.

For atopic dermatitis, some basic questions you might ask your doctor include:

Your doctor is likely to ask you several questions, including:

Here is the original post:
Atopic dermatitis (eczema) - Diagnosis and treatment ...

In a new study out of University of California San Diego School of Medicine, researchers have identified a universal strain of bacteria derived from healthy human skin that can treat the most common type of eczema, also known as atopic dermatitis.

In the paper published Feb. 22, 2021, in Nature Medicine, the research team investigated the safety and mechanisms of this certain bacteria in a first-in-human, Phase I, double-blinded clinical trial looking to treat people living with eczema. Of the 54 participants, two-thirds reported improvements in their symptoms, including fewer complaints of itchiness and inflammation.

The main question we wanted to answer was if this was safe. This was a safety study, said Richard Gallo, MD, PhD, Ima Gigli Distinguished Professor of Dermatology and chair of the Department of Dermatology at UC San Diego School of Medicine. We found exactly what we hoped to find. The eczema of participants who received the bacterial treatment improved and there were no adverse events.

Researchers screened more than 8,000 isolates of Staphylococcal bacteria derived from the skin of individuals without eczema, and identified a few strains that inhibited growth of Staphylococcal aureus, a pathogenic bacterium that aggravates skin conditions, such as eczema. These strains were evaluated for additional characteristics, such as decreased capacity to damage skin, and sensitivity to common antibiotics.

The screening resulted in the identification of a single strain of bacteria called Staphylococcus hominis A9 that could be used for the treatment of atopic dermatitis.

Thats how we found the universal strain. This was one out of 8,000 strains that were tested in a dish for their ability to kill Staphylococcal aureus and treat atopic dermatitis, said Gallo. And it worked.

The first tests were performed in animal models where mice were given an experimental version of eczema. Researchers then mixed Staphylococcus hominis with unscented lotion and applied the mixture to the mice twice daily for three days. After treatment, also known as bacteriotherapy, the mice were essentially cured of the eczema.

Success with these animal models led to the Phase I clinical trial using bacteriotherapy to treat 54 trial participants with eczema. Two-thirds of the participants showed a large reduction in S. aureus populations on their skin and improvement in their eczema.

This research is a unique approach to targeting the harmful Staphylococcal aureus on atopic dermatitis skin with beneficial bacteria, said study co-author Donald Leung, MD, allergist and immunologist at National Jewish Health and a co-author of the study. Its our hope this will help patients with eczema rid their skin of the harmful bacteria causing the inflammation. Future studies will determine if this new cream can be used for long periods of time to reduce the severity of eczema and improve the patients quality of life.

Healthy human skin is alive with bacteria there are more microorganisms living in and on the human body than there are human cells. Most microbes reside on human skin without causing harm, but in some people, bacterial pathogens can negatively alter a persons health.

According to the National Eczema Association, nearly 18 million people in the United States have atopic dermatitis, the most common form of eczema, which is a chronic, itchy rash that commonly appears on the arms, legs and cheeks.

From our research, weve determined this rational therapeutic approach for atopic dermatitis appears to be safe for people to use to treat their eczema, said Gallo. And its easy, too, because its just a cream and avoids the side effects of steroids and other drugs that target the immune system.

Co-authors of the study include: Teruaki Nakatsuji, Tissa R. Hata, Yun Tong, Joyce Y. Cheng, Faiza Shafiq, Anna M. Butcher, Secilia S. Salem, Samantha L. Brinton, UC San Diego; Amanda K. Rudman Spergel, National Institutes of Health; Keli Johnson, Brett Jepson, Agustin Calatroni, Gloria David, Rho Federal Systems Division, Inc.; Marco Ramirez-Gama, and Patricia Taylor, National Jewish Health.

This research was funded, in part, by the Atopic Dermatitis Research Network (U19AI117673) and National Institute of Health (R01AR076082, R01AR064781 and R01AI116576).

Disclosure: Richard L. Gallo is a cofounder, consultant, member of the scientific advisory board and holds equity in MatriSys Bioscience, a company that is developing skin bacteriotherapy.

The rest is here:
Last-Itch Effort: Fighting the Bacteria That Exacerbate Eczema with Bacteria - UC San Diego Health

MISSISSAUGA, ON, Feb. 23, 2021 /CNW/ - Sanofi Canada announced today that Health Canada has approved DUPIXENT (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis (AD) in children aged six to 11 years whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.3

"As the first biologic treatment for atopic dermatitis approved for this age group, DUPIXENT is a promising new option for treating children living with this chronic disease," says Dr. Melinda Gooderham, Dermatologist and Medical Director at the SKiN Centre for Dermatology. "Because it targets type 2 inflammation, the underlying cause of the disease, it may help young patients gain more control over their symptoms during childhood, a pivotal time in their development."

DUPIXENT is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins and is not an immunosuppressant. Data from DUPIXENT clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in AD, asthma, and severe chronic rhinosinusitis with nasal polyposis (CRSwNP).4

AD, the most common form of eczema, is an inflammatory disease classified by dry, itchy skin. In its moderate-to-severe form, it is characterized by rashes that can cover much of the body, and can include intense, persistent itching, skin lesions and skin dryness, cracking, redness or darkness, crusting and oozing.5 Inadequately controlled AD can have a physical, emotional and psychosocial impact, causing sleep disturbance, symptoms of anxiety and depression, and feelings of isolation.6

For children living with AD, studies showed that the impact extends beyond its physical symptoms. A survey conducted by the Eczema Society of Canada among Canadian children from infancy up to the age of 18 (and their caregivers) living with AD found that 70 per cent experienced loss of sleep due to their condition, 20 per cent missed school days and 30 per cent experienced anxiety.7 These factors can have a negative psychological impact on children, particularly in regard to their concentration and performance at school along with their willingness to socialize.8

"Atopic dermatitis is a chronic disease that has an indelible impact on all patients, both physically and psychologically, and can be devasting to children during a vulnerable time in their life," says Marissa Poole, Country Lead, Sanofi Canada and General Manager, Sanofi Genzyme Canada. "With this new indication, DUPIXENT now has the potential to help the many Canadians who experience this disease including children, adolescents and adults."

About DUPIXENT

Since its initial approval in 2017, DUPIXENT remains the only biologic medicine approved by Health Canada for the treatment of patients six years and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.9 DUPIXENT is also approved in Canada for the treatment of adult patients with severe CRSwNP and for the treatment of severe asthma in patients 12 years and older.10

DUPIXENT is jointly developed by Sanofi and Regeneron under a global collaboration agreement.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi entities in Canada employ approximately 2,000 people. In 2018, we invested more than $127 million in R&D in Canada, creating jobs, business and opportunity throughout the country.

Follow us on Twitter @SanofiCanada and on YouTube.

Sanofi, Empowering Life

References

___________________________________

1 Ben-Gashir MA, Seed PT, Hay RJ. Quality of life and disease severity are correlated in children with AD. Br J Dermatol. 2004;150(2):284-90. Available from https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2133.2004.05776.x?sid=nlm%3Apubmed. Accessed February 19, 2021.

2Eczema Society of Canada. Atopic Dermatitis Quality of Life Report. Available from https://eczemahelp.ca/wp-content/uploads/2019/02/ESC_Quality-of-Life-Report_Nov-2017-1.pdf. Accessed February 19, 2021.

3 DUPIXENT Canada Product Monograph. February 22, 2021.

4DUPIXENT Canada Product Monograph. February 22, 2021.

5 Mount Sinai. Patient Care Atopic Dermatitis. Available from http://www.mountsinai.org/patient-care/health-library/diseases-and-conditions/atopic-dermatitis#risk. Accessed February 19, 2021.

6 Eczema Society of Canada. Atopic Dermatitis Quality of Life Report. Available from https://eczemahelp.ca/wp-content/uploads/2019/02/ESC_Quality-of-Life-Report_Nov-2017-1.pdf. Accessed February 19, 2021.

7 Eczema Society of Canada. Atopic Dermatitis Quality of Life Report. Available from https://eczemahelp.ca/wp-content/uploads/2019/02/ESC_Quality-of-Life-Report_Nov-2017-1.pdf. Accessed February 19, 2021.

8 Sick Kids. Eczema: School and activities. Available from https://www.aboutkidshealth.ca/Article?contentid=1113&language=English. Accessed February 19, 2021.

9 DUPIXENT Canada Product Monograph. February 22, 2021.

10 DUPIXENT Canada Product Monograph. February 22, 2021.

SOURCE Sanofi Canada

Go here to read the rest:
Health Canada approves DUPIXENT (dupilumab injection) as the first biologic for the treatment of moderate-to-severe atopic dermatitis in children aged...

A MUM has described how her sons milk allergy left him skin blistered from head to toe and his poo like acid water.

Charlotte Smallwood, 25, says her baby Arthur screamed in pain and was "inconsolable" for seven months before he finally got the treatment he needed.

14

14

Doctors reportedly misdiagnosed Arthur, now 10 months old, with colic - when babies cry an abnormal amount - and acid reflux.

But Charlottes first child, three-year-old Thea, had suffered from both of these conditions, and she thought there was something more to Arthurs suffering.

The mum believed that milk was the problem but claims doctors continuously insisted Arthur did not have a cow's milk protein allergy (CMPA).

She and husband Lewis, 28, tried steroid creams, bath creams and milk formulas prescribed by doctors to help their constantly upset and sleep deprived baby - but to no avail.

Eventually, dermatologists at a children hospital urgently requested to see Arthur and were reportedly shocked and disgusted at his treatment to that point.

They prescribed a regime that worked miracles within 24 hours, according to Charlotte, who said Arthur was laughing and rolling around within a week.

Now, Arthur only has flare ups of his allergic symptoms.

14

14

14

14

Charlotte, from Romford, Essex, said: The eczema and reactions grew worse and worse, and in the end his skin was reacting to everything that went into or onto his body.

His skin and bowels would bear the brunt of his reactions he would have uncontrollable bowel movements that were like acid water, which left him blistered and raw.

It seemed as though whatever had just gone into him was trying to get out via his skin.

He couldnt do anything he never laughed, couldnt roll, sit up, play or grab things.

Charlotte felt overwhelmed trying to help her son when everything seemed to either have no affect or make him worse.

She said: The toughest part was watching Arthur scream, cry, scratch, throw himself around and bleed.

He would be absolutely uncontrollable and inconsolable.

14

14

14

Knowing that there wasnt anything that I could do to help my child was absolutely heartbreaking.

Charlotte noticed problems with baby Arthurs skin the day after he was born in April 2020.

His face was patchy and swollen, which doctors reportedly dismissed as baby acne and swelling due to being born by caesarean.

But when Arthur was taken home and started having infant formula, he began suffering episodes of screaming after eating, vomiting up the formula and arching his back in pain.

After swapping Arthur's milk back to pre-made bottles she saw an improvement in his behaviour but the symptoms soon started up again.

She tried over the counter colic and reflux medicines - after Arthurs GP suggested this was the cause - but nothing helped the poor baby.

Arthur was also suffering with severe cradle cap and constipation, and at four weeks old patches of eczema appeared on his cheeks and arms.

From one to four months old, I was back and forth on the phone to the doctor, Charlotte said.

He was given antibiotics, mild steroid creams, bath creams and over the counter creams nothing helped, it just made him worse and worse.

Some creams would even make him look as though he had been burned.

14

14

14

Cow's milk allergy - the facts

Cows milk protein allergy (CMPA) is one of the most common food allergies to affect babies and young children in the United Kingdom it is still rare.

Symptoms of CMPA often start in the early weeks and months of life.

It affects formula fed babies, but also breastfed babies in very rare cases.

CMPA is an abnormal response by the bodys immune system in which proteins in cows milk are recognised as a potential threat.

This can causethe immune system to be "sensitised". When this happens, there is the potential that when cow's milk is consumed the immune system remembers this protein and may react to it by producing allergic symptoms.

Allergic symptoms can affect one or more of thebodys systems, including the skin, digestive and, less commonly, breathing or blood circulation.

The symptoms can be "immediate", within a few minutes of consuming cows milk or up to two hours afterwards.

The other type of milk allergy happens when symptoms are "delayed", appearing up to 72 hours after cow's milk consumption.

This is caused by a different part of the immune system reacting ina different way.

If cows milk continues to be consumed in the diet, the immune system will continue to produce such symptoms over days or even weeks.

Source: Allergy UK

Unable to get a face-to-face appointment due to Covid-19 restrictions, Charlotte took Arthur to A&E.

Within 10 minutes, he was diagnosed with CMPA and severe infected eczema.

CMPA is when the immune system sees proteins in cows milk as a threat.

It can cause the immune system to be sensitised - it recognises the protein and produces allergic symptoms every time it sees the protein, according to Allergy UK.

This can affect the skin, digestive system, breathing and blood circulation.

Doctors prescribed Arthur a new formula, stronger steroid creams and bath creams, and within a week his skin started to clear up.

But when Charlotte tried to wean him off it, the skin issues came back with a vengeance.

She said: The sleep deprivation was something else I went seven months without sleeping more than three hours of broken sleep a night.

Arthur would just scratch, cry and scream all night long. I had to wrap his arm up close to his body just so he would stop scratching for five minutes.

His sister would get very upset watching him and it was tough trying to explain things to her.

She would give me a cuddle when I would break down in tears, which was a lot.

14

In October, Arthur was taken again to A&E after a bad reaction to a teething gel.

His dietician pushed for an appointment at Homerton University Hospital in London for allergy tests when he was seven months old.

Sadly, the condition of his skin was then too severe to carry out allergy testing and his body was 98 per cent covered in severe eczema.

We went home feeling very deflated and wondering how long we would have to wait for someone to see him again, Charlotte said.

But I received a phone call the next day from the Homerton childrens dermatology department asking me to take him there that second we couldnt believe it.

When Arthur was seen by the specialists, Charlotte said they were "shocked" and disgusted by how previous doctors had cared for his skin and couldn't understand how he had been left so long without proper treatment.

His new dermatologist gave him a strict skin routine which they said should help within one week.

It involved three different ointments, a gel for his scalp, and a special bath product.

Charlotte would apply steroid ointments over his whole face and body in the morning, followed by a cream 15 minutes later.

She had to reapply the cream every two hours, which dropped to every four hours in the second week.

14

The mum said: At the time, I was very sceptical and didnt believe them, but he was clear in just 24 hours.

By the end of the first week, he was laughing, rolling, sitting up, grabbing things and playing.

I could change his nappy on my own without him scratching and he slept through the night for the first time ever.

His big sister found it so amazing that she could finally play with her baby brother as she couldnt touch him before.

Now, sweet Arthur is flourishing and only suffers mild eczema flare-ups occasionally, caused by environmental factors such as dust and washing detergents.

He is still on the special formula but is weaning and loving all of his food, having had his allergies retested.

IMMUNE BOOSTAfter 2 doses of Pfizer's Covid jab 90% of Brits have 'high level of immunity'

RED ALERTHow red sky in the morning could be dangerous sign for people with asthma

FEEL THE BURNHow your heartburn could actually be a warning sign of cancer

YOUNG LUCKVaccine postcode lottery as healthy 20 and 30-year-olds called for Covid jabs

HOTSPOTSThe 52 places where Covid cases are rising again - check rates in your area now

Charlotte is careful to read food labels to ensure no dairy gets into Arthurs diet, which would cause another devastating flare-up.

She added: A lot of doctors seem very standoffish when it comes to CMPA, sort of like they dont believe its a real allergy.

I have come across many people and children like our family that have gone through the same situation.

But do not give up and dont be scared to go over somebodies head to get to where your child needs to be.

Arthur is now a happy, healthy 10-month-old who is thriving he has come so far.

More:
Mums agony at sons screams from blistered skin and bowel movements like acid water - The Sun

Eczema Therapeutics Market Report 2021: To Know the impact of COVID-19 on the global market, Request For Free Sample

The Eczema Therapeutics Market Report is a systematic survey of the global Eczema Therapeutics market that depicts shows the current state of the business at the observatory. The Supply and demand, revenue estimates, and volume share are widely covered in the report. This predicts market progress over the forecast year 2020 to 2027. The report includes key strategies of companies operating in the market and their impact analysis. The report features an outline of the determined vendors of the market along with an overview of the major market players. Thekey players in the Eczema Therapeutics market areEncore Dermatology Inc, Eli Lilly and Co, Sanofi, LEO Pharma AS, Alliance Pharma Plc, Pfizer Inc, AbbVie Inc, Mylan NV, Bausch Health Companies Inc, Bayer AG.The report contains inventions that provide revenue segmentation and business overview, layouts for key market players. It takes into account the latest enhancements in the global Eczema Therapeutics market while assessing the market share of key players over the forecast period 2021-2027. The report estimates growth in the global Eczema Therapeutics market by estimating the limits and strengths of key players through SWOT analysis. In addition, the report highlights key product overviews and Market segments [By Product Type: Atopic Dermatitis, Contact Dermatitis, Others], and global market subsegment By Application: Hospital, Clinic, Others of the global market

Download FREE Sample Report:@ https://www.globalmarketers.biz/report/life-sciences/global-eczema-therapeutics-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/154779#request_sample

This study analyzes the economic adverse effects of COVID-19 with Eczema Therapeutics supply chain scenarios, global demand, and consumers are analyzed in this report. It also provides a robust Eczema Therapeutics business strategy adopted by industry players to gain traction in the industry. It provides detailed info on marketing channels, upstream raw material suppliers, and downstream buyer analysis.The extensive assessment of Eczema Therapeutics manufacturing processes, consumption patterns, company profiles, and gross margins has been analyzed in this study. It also provides additional evaluation/analysis on pricing and demand for each product type, application, the end-users study is also offered in this research. The opportunities, restraints, growth drivers, future trends are presented effectively by Global Marketers

Main highlights from the table of contents:1. Market overview

MarketScope

Definition, classification, purpose

Eczema Therapeutics market momentum, opportunity map analysis

Analysis of market concentration and maturity

2. Market segmentation

Industry classification by top companies

By product type

Depends on the application and end-user

3. Regional diversification of the Eczema Therapeutics industry

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Other parts of the world

4. Competitive analysis

Market share, sales, revenue analysis

Import-Export details, supply and demand statistics

M & A, growth strategies, opportunities, and risk assessment

5. Important data coverage by region

Volume and value analysis

Consumption and market share survey

Revenue, price trends, and market size assessment

6. Manufacturer/Top Company Profile

Business overview

Eczema Therapeutics product analysis

Sales by region

Price, revenue, gross profit

7. Global Eczema Therapeutics Market Forecast by Type, Application, and End User

Forecast by size, share, and revenue

Predict growth opportunities, investment scope, and development

Pricing, consumption, and volume forecasts for Eczema Therapeuticss

8. Important survey results and survey methods

9. Reliable data source

10. Conclusions, analysts opinions, and appendices

Browse Detailed TOC https://www.globalmarketers.biz/report/life-sciences/global-eczema-therapeutics-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/154779#table_of_contents

https://neighborwebsj.com/

Visit link:
Eczema Therapeutics Market 2020, Global Statistics, Facts and Figures, Investment Trends, Analysis Of Major Manufacturer Trends and Forecast By 2026 -...

Showering is a significant use of water in American homes. On average, individuals typically take 8-10 minute showers every day, using about 17 gallons of water each time.

If everyone in the city of Flagstaff with its current population took showers like that - 365 days a year - it would add up to almost 460 million gallons of water annually; an amount equivalent to about 10% of the water in Lake Mary when its filled to the brim.

For residents of the Prescott Quad Cities area, those long showers add up to just over 800 million gallons a year, or about half the water in Watson Lake when its full.

Water consumption in Arizona has held steady and even declined over the last few decade - in part because of the Groundwater Management Act of 1980, which restricted irrigation on new farmland in urban areas. Even so, showering can still account for up to 20% of a persons average use of 84 gallons a day.

Cutting down on personal water usage can be as simple as installing low flow shower heads and showering half as long or half as often. An added bonus of not showering every day is that its good for our skins microbiome.

These natural communities on our skin, create antimicrobial substances that compete with unwanted pathogens. A healthy microbiome helps protect us from those bugs and can reduce skin infections like eczema.

Taking shorter, less frequent showers is not only a good way to conserve local water resources, it can also be good for our health.

Read more:
Earth Notes: The Benefits Of Showering Less - KNAU Arizona Public Radio

'); $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).append(""+val.title+""); // if (window.location.hostname == "www.kmov.com" || window.location.hostname == "www.kctv5.com" || window.location.hostname == "www.azfamily.com" || window.location.hostname == "www.kptv.com" || window.location.hostname == "www.fox5vegas.com" || window.location.hostname == "www.wfsb.com") { if (val.poly != "" && val.polyimg != "") { $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).append('"+val.ihtml+""); $("#expandable-weather-block .weather-index-alerts").show(); $("#expandable-weather-block .modal-body h2").css({"font-family":"'Fira Sans', sans-serif", "font-weight":"500", "padding-bottom":"10px"}); $("#expandable-weather-block .modal-body p").css({"font-size":"14px", "line-height":"24px"}); $("#expandable-weather-block .modal-body span.wxalertnum").css({"float":"left", "width":"40px", "height":"40px", "color":"#ffffff", "line-height":"40px", "background-color":"#888888", "border-radius":"40px", "text-align":"center", "margin-right":"12px"}); $("#expandable-weather-block .modal-body b").css("font-size", "18px"); $("#expandable-weather-block .modal-body li").css({"font-size":"14px", "line-height":"18px", "margin-bottom":"10px"}); $("#expandable-weather-block .modal-body ul").css({"margin-bottom":"24px"}); $("#expandable-weather-block .modal-body pre").css({"margin-bottom":"24px"}); $("#expandable-weather-block .modal-body img").css({"width":"100%", "margin-bottom":"20px", "borderWidth":"1px", "border-style":"solid", "border-color":"#aaaaaa"}); $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).css({"borderWidth":"0", "border-bottom-width":"1px", "border-style":"dashed", "border-color":"#aaaaaa", "padding-bottom":"10px", "margin-bottom":"40px"}); }); } function parseAlertJSON(json) { console.log(json); alertCount = 0; if (Object.keys(json.alerts).length > 0) { $("#mrd-wx-alerts .modal-body ").empty(); } $.each(json.alerts, function(key, val) { alertCount++; $("#mrd-wx-alerts .alert_count").text(alertCount); $("#mrd-wx-alerts .modal-body ").append(''); $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(""+val.title+""); // if (window.location.hostname == "www.kmov.com" || window.location.hostname == "www.kctv5.com" || window.location.hostname == "www.azfamily.com" || window.location.hostname == "www.kptv.com" || window.location.hostname == "www.fox5vegas.com" || window.location.hostname == "www.wfsb.com") { if (val.poly != "" && val.polyimg != "") { $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(''); } else if (val.fips != "" && val.fipsimg != "") { // $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(''); } // } //val.instr = val.instr.replace(/[W_]+/g," "); $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(val.dhtml+"

Instruction

Continue reading here:
How to treat your stressed-out skin | US & World News | kctv5.com - KCTV Kansas City

Kawakawa (Piper excelsum) is traditionally used by the indigenous Maori for medical purposes such as pain relief, alleviating eczema, and rheumatism. It is also used as a spice in the everyday cuisine.

Researchers at the Liggens Institute, University of Auckland, have been studying the plant for years and their project was recently granted nearly NZ$1.3m (US$949k) by the High-Value Nutrition (HVN) Science Challenge.

The eventual goal is to launch a functional drink by homegrown beverage firm Chia Sisters, while Wakatu Incorporation will export the product to Japan and South East Asia. The kawakawa used in this project is the Aotearoa New Zealand native species.

At the moment, the researchers are now planning two trials to test the optimal dosage amounts and the best suited beverage formats.

Kawakawa contains pharmacokinetic metabolites with interesting structures and properties. We suspect it could increase the uptake of nutrients or make nutrients more bioavailable in the body.

Some of its compounds can affect the way we metabolise glucose and fatty acids, lead researcher of the project, Dr Chris Pook from the Liggens Institute told NutraIngredients-Asia.

The first trial, which will take place later this year, will be a one-day study that looks at the short-term effects of kawakawa on fatty acid and glucose metabolism.

Participants will need to try out kawakawa in varying dosage amounts and dosage formats.

From here, researchers will measure the participants energy expenditure, as well as the amount of heat and carbon dioxide the body produces, before deciding the formats and dosages for the second trial.

Running for six weeks, the second trial will track the effects of the kawakawa beverage over time.

As part of the project, the researchers are also finding out ways to maximise their extraction of kawakawas bioactives.

The industry partner involved, Wakatu Incorporation, also intends to make functional claims on the final product.

For instance, when exporting to Japan, it plans to register the product as a Foods with Function Claims (FFC), Miriana Stephens, general manager at Wakatu Incorporation said.

This is also the first time the distributor is working on a functional beverage.

We export New Zealand food and beverages including seafood, wines, and natural foods to over 40 countries, the functional beverage space is completely new for us and we will work closely with our customer on refining the product, she said.

Ready-to-drink kawakawa beverages already exist in the New Zealand market.

Last year, Atutahi, a local carbonated drink brand containing kawakawa was launched.

Read more:
Kawakawa innovation: NZ researchers to trial beverage for immunity, metabolic health gains - BeverageDaily.com